Details of Disease

General Information of Disease (ID: DISVBLBO)

• Disease Name: Hyperlipoproteinemia
• Synonyms: hyperlipoproteinemia
• Disease Class: 5C80: Hyper-lipoproteinaemia
• Definition: An elevated concentration of lipoproteins.
• Disease Hierarchy:
  DIS71G5H: Metabolic disorder
  DISVBLBO: Hyperlipoproteinemia
• ICD Code:
  ICD-11: ICD-11: 5C80
  ICD-10: ICD-10: E78.4, E78.5
  Expand ICD-11: '5C80
  Expand ICD-10: 'E78.4; 'E78.5
  Expand ICD-9: 272
• Disease Identifiers:
  MONDO ID: MONDO_0037748
  MESH ID: D006951
  UMLS CUI: C0020476
  MedGen ID: 9363
  HPO ID: HP:0010980
  SNOMED CT ID: 3744001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ciprofibrate	DMGC5DB	Approved	Small molecular drug	[1]
Extrothyroxine	DMODEG9	Approved	NA	[2]
Volanesorsen	DM1YEPS	Approved	Antisense oligonucleotide	[3]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Pelacarsen	DMY757D	Phase 3	Antisense oligonucleotide	[4]
AKCEA-APO(a)-LRX	DMMOFX1	Phase 2	NA	[5]
SC401	DM9G2EV	Phase 2	NA	[5]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 20 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
F7	TTF0EGX	Limited	Biomarker	[6]
HSD11B1	TTN7BL9	Limited	Biomarker	[7]
PON1	TT9LX82	Limited	Biomarker	[8]
SDC1	TTYDSVG	Limited	Biomarker	[9]
SERPINC1	TT4QPUL	Limited	Biomarker	[10]
ABCA1	TTJW1GN	Strong	Biomarker	[11]
ABCG5	TTKZ7WY	Strong	SusceptibilityMutation	[12]
ADIPOQ	TTXKA7D	Strong	Therapeutic	[13]
APOC3	TTXOZQ1	Strong	Biomarker	[14]
CETP	TTFQAYR	Strong	Biomarker	[15]
CRP	TTWRN6M	Strong	Biomarker	[13]
CYP2E1	TTWVHQ5	Strong	Biomarker	[16]
LCAT	TTGZ91P	Strong	Biomarker	[17]
LEP	TTBJEZ5	Strong	Biomarker	[18]
LPL	TTOF3WZ	Strong	Therapeutic	[19]
MANF	TT56RYE	Strong	Biomarker	[20]
MTTP	TTUS1RD	Strong	Biomarker	[21]
PPARA	TTJ584C	Strong	Biomarker	[22]
VCAM1	TTHCEF6	Strong	Biomarker	[23]
APOB	TTN1IE2	Definitive	Biomarker	[24]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC27A1	DTKDTML	Limited	Biomarker	[25]

This Disease Is Related to 12 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
APOBEC1	OTY8QX2R	Limited	Biomarker	[26]
GFPT1	OTQBDO45	Limited	Biomarker	[27]
KL	OTD4VWU6	Limited	Biomarker	[28]
RGN	OTD04KB1	Limited	Biomarker	[29]
SERPINF2	OTZGAF8B	Limited	Biomarker	[30]
SHC1	OT1J5IRN	Limited	Biomarker	[31]
SMARCD1	OTHFFT6G	Limited	Biomarker	[32]
APOA5	OTEVKLVA	Strong	Genetic Variation	[33]
APOC2	OTLINYIQ	Strong	Genetic Variation	[34]
CREB3L3	OTDMU3GP	Strong	Biomarker	[35]
GPIHBP1	OTDF8R2M	Strong	Genetic Variation	[36]
LIPC	OTZY5SC9	Definitive	Biomarker	[37]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3438).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8681).
• [4] ClinicalTrials.gov (NCT05900141) A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.. U.S.National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Experimental arterial thrombosis in genetically or diet induced hyperlipidemia in rats--role of vitamin K-dependent clotting factors and prevention by low-intensity oral anticoagulation.Thromb Haemost. 2001 Dec;86(6):1440-8.
• [7] Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.Biochem Biophys Res Commun. 2004 Jan 16;313(3):594-9. doi: 10.1016/j.bbrc.2003.11.160.
• [8] Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin. 2004 Aug;20(8):1321-7.
• [9] Adenovirus-mediated hepatic syndecan-1 overexpression induces hepatocyte proliferation and hyperlipidaemia in mice.Liver Int. 2007 May;27(4):569-81. doi: 10.1111/j.1478-3231.2007.01442.x.
• [10] Development of hyperfibrinogenemia in spontaneously hypertensive and hyperlipidemic rats: a potentially useful animal model as a complication of hypertension and hyperlipidemia.Exp Anim. 2007 Jan;56(1):1-10. doi: 10.1538/expanim.56.1.
• [11] Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo.Eur J Pharmacol. 2006 Dec 3;551(1-3):80-6. doi: 10.1016/j.ejphar.2006.08.048. Epub 2006 Sep 6.
• [12] The missense mutation in Abcg5 gene in spontaneously hypertensive rats (SHR) segregates with phytosterolemia but not hypertension.BMC Genet. 2005 Jul 18;6:40. doi: 10.1186/1471-2156-6-40.
• [13] [Effect of electroacupuncture intervention on blood-lipid, high-sensitivity C-reactive protein and adiponectin levels in hyperlipidemia rats].Zhen Ci Yan Jiu. 2013 Oct;38(5):365-8, 385.
• [14] Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest. 1991 May;87(5):1724-31. doi: 10.1172/JCI115190.
• [15] Studies on the plasma lipid profiles, and LCAT and CETP activities according to hyperlipoproteinemia phenotypes (HLP).Atherosclerosis. 2001 Dec;159(2):381-9. doi: 10.1016/s0021-9150(01)00513-5.
• [16] Coexistence of hyperlipidemia and acute cerebral ischemia/reperfusion induces severe liver damage in a rat model.World J Gastroenterol. 2012 Sep 21;18(35):4934-43. doi: 10.3748/wjg.v18.i35.4934.
• [17] Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats.J Pharm Pharm Sci. 2003 May-Aug;6(2):189-97.
• [18] Change in lipid components in the adipose and liver tissues of regucalcin transgenic rats with increasing age: suppression of leptin and adiponectin gene expression.Int J Mol Med. 2007 Sep;20(3):323-8.
• [19] [Modulating effects of shenmai injection on serum lipids in rats with hyperlipemia].Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2016 Mar 8;32(3):230-233. doi: 10.13459/j.cnki.cjap.2016.03.011.
• [20] Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3.Clin Chem. 1979 Feb;25(2):279-84.
• [21] Triglyceride-lowering effect of pitavastatin [corrected] in a rat model of postprandial lipemia.Eur J Pharmacol. 2002 May 24;444(1-2):107-13. doi: 10.1016/s0014-2999(02)01547-9.
• [22] Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia.J Lipid Res. 2000 Jun;41(6):945-52.
• [23] [Impact of fenofibrate on NO and endothelial VCAM-1 expression in hyperlipidemic rats].Nan Fang Yi Ke Da Xue Xue Bao. 2007 Dec;27(12):1872-4.
• [24] Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project.Clin Exp Rheumatol. 2019 Sep-Oct;37(5):774-782. Epub 2019 Feb 15.
• [25] Fiber type- and fatty acid composition-dependent effects of high-fat diets on rat muscle triacylglyceride and fatty acid transporter protein-1 content.Metabolism. 2004 Aug;53(8):1032-6. doi: 10.1016/j.metabol.2004.03.011.
• [26] Effects of a thyromimetic on apolipoprotein B-100 in rats.J Mol Endocrinol. 2000 Dec;25(3):299-308. doi: 10.1677/jme.0.0250299.
• [27] Effect of sucrose and saturated-fat diets on mRNA levels of genes limiting muscle fatty acid and glucose supply in rats.Lipids. 2006 Jan;41(1):55-62. doi: 10.1007/s11745-006-5070-1.
• [28] Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases.Cell Mol Life Sci. 2000 May;57(5):738-46. doi: 10.1007/s000180050038.
• [29] Hyperlipidemia is induced in regucalcin transgenic rats with increasing age.Int J Mol Med. 2004 Oct;14(4):647-51.
• [30] Changes in coagulative and fibrinolytic activities in Triton WR-1339-induced hyperlipidemia in rats.Jpn J Pharmacol. 1990 Feb;52(2):353-61. doi: 10.1254/jjp.52.353.
• [31] Cholesterol diet-induced hyperlipidemia influences gene expression pattern of rat hearts: a DNA microarray study.FEBS Lett. 2004 Mar 26;562(1-3):99-104. doi: 10.1016/S0014-5793(04)00189-9.
• [32] Hyperlipidaemia impairs the circadian clock and physiological homeostasis of vascular smooth muscle cells via the suppression of Smarcd1.J Pathol. 2014 Jun;233(2):159-69. doi: 10.1002/path.4338. Epub 2014 Mar 28.
• [33] Mutations of the apolipoprotein A5 gene with inherited hypertriglyceridaemia: review of the current literature.Curr Med Chem. 2012;19(36):6163-70. doi: 10.2174/092986712804485719.
• [34] The apolipoprotein C-II variant apoC-IILys19-->Thr is not associated with dyslipidemia in an affected kindred.Clin Genet. 1994 Jun;45(6):292-7. doi: 10.1111/j.1399-0004.1994.tb04033.x.
• [35] CREBH mediates metabolic inflammation to hepatic VLDL overproduction and hyperlipoproteinemia.J Mol Med (Berl). 2017 Aug;95(8):839-849. doi: 10.1007/s00109-017-1534-4. Epub 2017 Apr 28.
• [36] Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650).Lipids Health Dis. 2007 Sep 20;6:23. doi: 10.1186/1476-511X-6-23.
• [37] Association of an intronic haplotype of the LIPC gene with hyperalphalipoproteinemia in two independent populations.J Hum Genet. 2008;53(3):193-200. doi: 10.1007/s10038-007-0236-0. Epub 2007 Dec 27.